Ann Hematol (2017) 96:1563–1568 DOI 10.1007/s00277-017-3062-2 LETTER TO THE EDITOR Calcineurin inhibitor-free GVHD prophylaxis with sirolimus and mycophenolate mofetil combination 1 2 1 Neeraj Saini & Rajneesh Nath & Jan Cerny Received: 12 January 2017 /Accepted: 3 July 2017 /Published online: 15 July 2017 Springer-Verlag GmbH Germany 2017 Dear Editor, We evaluated outcomes of a CNI-free GVHD prophylaxis Acute or chronic graft-versus-host disease (GVHD) has regimen of SIR-MMF [sirolimus (SIR) combined with myco- been the nemesis for allogeneic hematopoietic stem cell trans- phenolate mofetil (MMF)] for patients with hematological plantation (HSCT). Initial efforts in GVHD prophylaxis malignancies. A total of six patients (four males and two fe- established cyclosporine A (CsA), a calcineurin inhibitor males) underwent reduced intensity conditioning (RIC) (CNI), to be more effective as a single agent compared to matched (10/10) unrelated donor peripheral blood stem cell methotrexate . The combination of cyclosporine, a CNI, transplant (PBSCT) at our institution from April to June in the with methotrexate has been the standard regimen for acute year 2011. The median age of the group was 68 years (65– GVHD prophylaxis for the last three decades . Prior studies 77 years). Three patients had acute myelogenous leukemia in of
Annals of Hematology – Springer Journals
Published: Jul 15, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera